… unresectable hepatocellular carcinoma who had not previously received systemic treatment
were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or …

… cancer has already spread and are less likely to survive. A new treatment method using two
kinds of antibodies, atezolizumab and bevacizumab… with advanced liver cancer. In this review…

… IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly … with
sorafenib in patients with unresectable hepatocellular carcinoma at the primary analysis (after a …

… suggest that combining atezolizumab with bevacizumab can … patients with unresectable
hepatocellular carcinoma. To find … done to compare atezolizumab and bevacizumab combination …

… atezolizumab for use in combination with bevacizumab, for … advanced or metastatic
hepatocellular carcinoma (HCC) with … atezolizumab plus bevacizumab (atezolizumab-bevacizumab) …

… Molecular correlates of clinical response to atezolizumab-bevacizumab To explore potential
biomarkers associated with clinical response or resistance to atezolizumab + bevacizumab, …

… Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy for patients
with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness and safety in …

Background Ph 1b data has shown promising efficacy and safety for atezo + bev in unresectable
HCC pts who have not received prior systemic therapy. Here, we report the primary …

… the combination of atezolizumab–bevacizumab, sorafenib, … approved the use of
atezolizumab–bevacizumab, sorafenib, … including atezolizumab plus a bevacizumab combination …

… combination with other agents (eg bevacizumab, lenvatinib), have … The combination of
atezolizumab and bevacizumab has … with atezolizumab, VEGF blockade with bevacizumab and a …